- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approxim...
-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and mul...
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hour...
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis)...
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-depende...
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets a...
- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a on...
-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted me...
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approxima...
-Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full a...
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of ...
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis...
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approxim...
- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was sign...
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis...
- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight r...
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral disc...
- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater dru...
- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting bothGLP-1 recep...
- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resul...